| 2003 | Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2006 | Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer | ONCOLOGY REPORTS |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2023 | Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2014 | Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer | CANCER |
| 2020 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study | ANNALS OF ONCOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
| 2003 | Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2009 | Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma | ONCOLOGY |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2007 | Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
| CANCER |
| 2017 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) | ESMO OPEN |
| 2012 | Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram
| NEURO-ONCOLOGY |
| 2015 | Prediction of short- and long-term survival for advanced cancer patients after ICU admission | SUPPORTIVE CARE IN CANCER |
| 2016 | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | BREAST |
| 2020 | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
| CANCER RESEARCH AND TREATMENT |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2019 | Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
| CANCER RESEARCH AND TREATMENT |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Regarding the article by Rugo Reply
| ONCOLOGIST |
| 2021 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs | Clinical and Translational Science |
| 2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
| JAMA ONCOLOGY |
| 2007 | Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells | JOURNAL OF CONTROLLED RELEASE |
| 2023 | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
| ESMO OPEN |
| 2021 | Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective | ANNALS OF SURGERY |
| 2008 | Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| BMC CANCER |
| 2021 | Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
| BRITISH JOURNAL OF CANCER |
| 2009 | Sonographic surveillance for the detection of contralateral metachronous breast cancer in an Asian population | AMERICAN JOURNAL OF ROENTGENOLOGY |
| 2001 | Squamous Cell Carcinoma of the Cornea
| YONSEI MEDICAL JOURNAL |
| 2021 | Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
| CANCER RESEARCH AND TREATMENT |
| 2023 | Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
| JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
| 2023 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2018 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control | CANCER NURSING |
| 2020 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial | JAMA ONCOLOGY |
| 2008 | The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. | LUNG CANCER |
| 2022 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
| FUTURE ONCOLOGY |
| 2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
| CLINICAL CANCER RESEARCH |
| 2009 | US surveillance of regional lymph node recurrence after breast cancer surgery. | RADIOLOGY |
| 2010 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
| 2006 | 난소에 발생한 간양 암종 1예 | Korean Journal of Gynecologic Oncology (부인종양) |
| 2001 | 성문하 협착을 동반한 베게너 육아종증 1예
| Journal of the Korean Rheumatism Association (대한류마티스학회지) |
| 2015 | 성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상
| Korean Journal of Clinical Oncology (대한임상종양학회지) |
| 2019 | 차세대 염기서열 분석법과 항암요법
| JOURNAL OF THE KOREAN MEDICAL ASSOCIATION |
